GRAIL

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, GRAIL sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).

5 total trials 1 currently recruiting 2 completed upper quartile by trial count

GRAIL: 5 sponsored US clinical trials, 1 recruiting.

GRAIL sponsors 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 2 completed. The most-studied condition in this pipeline is Cancer, with 3 trials.

Upper-quartile sponsor footprint

GRAIL sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

5 total, page 1 of 1

RECRUITING NA

Galleri® in the Medicare Population.

NCT05673018
ACTIVE NOT RECRUITING NA

PATHFINDER 2: a Multi-Cancer Early Detection Study

NCT05155605
ACTIVE NOT RECRUITING

REFLECTION: A Clinical Practice Learning Program for Galleri®

NCT05205967
COMPLETED NA

Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test Into Clinical Practice

NCT04241796
COMPLETED

The STRIVE Study: Development of a Blood Test for Early Detection of Multiple Cancer Types

NCT03085888

Therapeutic Areas

Cancer 3
Early Detection of Cancer 2

What is open in the GRAIL pipeline

1 recruiting of 5 indexed (20% open); 2 completed (40%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Cancer (3 trials), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

GRAIL: open-pipeline peers nationwide

Peers matched on 5 registered trials and 20% open enrollment, not the therapeutic-area sidebar.

GRAIL sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 4.95.05.055.05.05.1 0%5%10%15%20%25% Total trials Recruiting share GRAIL4YouandMeAbbott Rapid DxAccess Business GroupAcera SurgicalAlign TechnologyAltruBioAlvernia UniversityAmazentis
GRAIL sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

GRAIL sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 5 trials (± recruiting share)

Sponsors near 20% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this GRAIL page

5 registered trials is a research-attention snapshot, not an endorsement of GRAIL or any single study.

  • 1 of GRAIL's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Cancer is the condition GRAIL studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

GRAIL pipeline card: 5 registered trials from official public datasets.Report a data error.